Leerink Partnrs Issues Optimistic Outlook for ACAD Earnings

Key Points

• Leerink Partners raised their Q4 2025 earnings per share (EPS) estimate for ACADIA Pharmaceuticals to $0.09, up from a prior forecast of $0.08, amidst a full-year consensus estimate of $0.70 EPS.
• Institutional investors own approximately 96.71% of ACADIA Pharmaceuticals' stock, with notable recent increases in stakes from firms like GAMMA Investing LLC and Rhumbline Advisers.
• ACADIA Pharmaceuticals reported a Q2 EPS of $0.16, exceeding analysts' expectations of $0.14, alongside a 9.4% year-over-year revenue increase.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities researchers at Leerink Partnrs boosted their Q4 2025 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a report issued on Monday, October 6th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings per share of $0.09 for the quarter, up from their previous forecast of $0.08. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals' FY2026 earnings at $0.55 EPS, FY2028 earnings at $1.25 EPS and FY2029 earnings at $1.00 EPS.

Other equities research analysts have also recently issued reports about the company. HC Wainwright restated a "buy" rating and set a $32.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, June 26th. Royal Bank Of Canada increased their price objective on ACADIA Pharmaceuticals from $39.00 to $40.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. Needham & Company LLC cut their price objective on ACADIA Pharmaceuticals from $30.00 to $28.00 and set a "buy" rating on the stock in a report on Wednesday, September 24th. Oppenheimer reissued a "market perform" rating and issued a $22.00 price objective (up from $19.00) on shares of ACADIA Pharmaceuticals in a report on Thursday, June 26th. Finally, TD Cowen increased their price objective on ACADIA Pharmaceuticals from $35.00 to $39.00 and gave the company a "buy" rating in a report on Thursday, September 11th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $29.12.

ACADIA Pharmaceuticals Stock Performance

ACAD stock opened at $21.31 on Thursday. The company has a market cap of $3.60 billion, a price-to-earnings ratio of 16.02, a P/E/G ratio of 7.57 and a beta of 0.75. The business's 50-day moving average is $24.07 and its two-hundred day moving average is $20.92. ACADIA Pharmaceuticals has a fifty-two week low of $13.40 and a fifty-two week high of $26.65.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.14 by $0.02. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%.The company had revenue of $264.57 million for the quarter, compared to analysts' expectations of $263.07 million. During the same period last year, the firm posted $0.20 earnings per share. ACADIA Pharmaceuticals's revenue was up 9.4% compared to the same quarter last year.

Institutional Trading of ACADIA Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ACAD. GAMMA Investing LLC boosted its stake in shares of ACADIA Pharmaceuticals by 11,981.0% in the first quarter. GAMMA Investing LLC now owns 58,351 shares of the biopharmaceutical company's stock worth $969,000 after acquiring an additional 57,868 shares during the last quarter. Rhumbline Advisers lifted its position in ACADIA Pharmaceuticals by 100.9% during the first quarter. Rhumbline Advisers now owns 352,716 shares of the biopharmaceutical company's stock worth $5,859,000 after buying an additional 177,188 shares in the last quarter. Yousif Capital Management LLC purchased a new position in ACADIA Pharmaceuticals during the first quarter worth approximately $764,000. Assenagon Asset Management S.A. purchased a new position in ACADIA Pharmaceuticals during the first quarter worth approximately $60,845,000. Finally, Exchange Traded Concepts LLC purchased a new position in ACADIA Pharmaceuticals during the first quarter worth approximately $29,000. 96.71% of the stock is owned by institutional investors and hedge funds.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 3,498 shares of the firm's stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $23.65, for a total value of $82,727.70. Following the sale, the executive vice president directly owned 43,447 shares of the company's stock, valued at approximately $1,027,521.55. This trade represents a 7.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Elizabeth A. Garofalo sold 1,600 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $25.98, for a total value of $41,568.00. Following the completion of the sale, the director directly owned 25,382 shares in the company, valued at approximately $659,424.36. The trade was a 5.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 27,098 shares of company stock worth $678,256. 26.50% of the stock is owned by corporate insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.